Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M140Revenue $M0.0Net Margin (%)-303,930.0Z-Score15.3
Enterprise Value $M79.5EPS $-1.3Operating Margin %-303,930.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-243,950.0Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %-16.1Quick Ratio14.9Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-21.4Current Ratio14.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-38.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-40.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M23.1ROI % (ttm)-56.0Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

RPRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Masterson Nola EDirector 2014-09-15Buy200$14.34-56.69 view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-55.16 view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-55.36 view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-58.52 view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-65.56 view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-65.31 view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-73.87 view
Anderson KatherineCFO 2013-02-01Buy1,000$11.89-47.77 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-14Buy59,500$7.38-15.85 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-11Buy170,000$6.35-2.2 view

Press Releases about RPRX :

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
comment on RPRX Mar 06 2013 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
promotes testosteron Jun 22 2011 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

More From Our Partners
Stocks Hitting 52-Week Lows Oct 17 2014 - BENZINGA
Morning Market Losers Oct 17 2014 - BENZINGA

More From Other Websites
Nasdaq stocks posting largest percentage increases Oct 22 2014
Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile Oct 21 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 21 2014
4:02 pm Repros Therapeutics: results from long-term study of Androxal exhibit positive safety... Oct 21 2014
Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile Oct 21 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Oct 20 2014
INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP Oct 20 2014
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics... Oct 20 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Oct 17 2014
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros... Oct 17 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros... Oct 17 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 17 2014
Repros Therapeutics shares drop on drug application setback Oct 17 2014
[$$] Repros Therapeutics Shares Drop Premarket Oct 17 2014
Upcoming FDA Meeting to be Type C Meeting Oct 16 2014
Upcoming FDA Meeting to be Type C Meeting Oct 16 2014
Can Repros Therapeutics Shares Still More Than Double? Sep 29 2014
Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% Sep 29 2014
US STOCKS-Biotech among biggest Nasdaq gainers Sep 26 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Sep 26 2014
FDA Schedules Type B Pre-NDA Meeting With Repros Sep 26 2014
Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary... Sep 25 2014
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Sep 22 2014
[$$] FDA Recommendation Doesn't Apply to Androxal, Repros Says Sep 22 2014
Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces... Sep 22 2014
Rite Aid Plunges As Full-Year Outlook Dims Sep 18 2014
Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the... Mar 17 2014
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results Mar 13 2014
Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism Feb 10 2014
Repros Therapeutics rises on Androxal update Feb 06 2014
Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary... Feb 06 2014
Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel Jan 08 2014
Repros Adds Marketing and Commercialization Expertise to Board of Directors Dec 19 2013
Repros to Present Data on the Benefits of Testosterone Restoration With Androxal(R) Compared to T... Nov 25 2013
FDA Schedules Face to Face Meeting With Repros to Discuss Androxal(R) Efficacy Nov 25 2013
Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results Nov 07 2013
Repros Receives FDA Guidance for Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program Nov 04 2013

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK